A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer (OrigAMI-2)
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
- Colorectal Neoplasms
At a glance
- Phase
- Phase 3
- Study type
- Interventional
- Sponsor
- Janssen Research & Development, LLC
- Enrolment target
- 1,000
- Started
- 18 October 2024
- Main results due (estimated)
- 15 December 2028
- Study ends (estimated)
- 20 January 2032
- Allocation
- Randomized
- Design
- Parallel
- Purpose
- Treatment
- Masking
- None
- Sites
- 239 · 5 in India
- First posted
- 29 October 2024
- Registry updated
- 3 November 2026
Can you take part?
- Aged 18 years and over.
- Open to any sex.
- You need the condition being studied. Healthy volunteers are not accepted.
Age groups: adult, older adult.
These are the headline rules. Every study has a longer list, and whether you are eligible is decided by the research team at the site, never by this page.
Read the full eligibility criteria
Inclusion Criteria: * Have histologically or cytologically confirmed adenocarcinoma of the left-sided colorectal cancer. Participants must have unresectable or metastatic disease * Determined to have Kirsten rat sarcoma viral oncogene (KRAS), neuroblastoma RAS viral oncogene homolog (NRAS), and v-raf murine sarcoma viral oncogene homolog B (BRAF) wild-type (WT) tumor by local and/or central testing (if available) * Must agree to the submission of fresh tumor tissue * Have measurable disease according to RECIST v1.1 * Has not received any prior systemic therapy for unresectable or metastatic colorectal cancer (CRC). Prior adjuvant/neoadjuvant therapy in the non-metastatic disease is permitted. However, the last course of adjuvant or neoadjuvant chemotherapy must have concluded greater than (\>) 12 months prior to CRC recurrence/metastases * Have an eastern cooperative oncology group (ECOG) performance status (PS) of 0 or 1 Exclusion Criteria: * Has medical history of (noninfectious) interstitial lung disease (ILD) /pneumonitis/pulmonary fibrosis or has current ILD/pneumonitis/pulmonary fibrosis, or where suspected ILD/pneumonitis/pulmonary fibrosis cannot be ruled out by imaging at screening * Has known allergies, hypersensitivity, or intolerance to excipients of any of the following: (a) amivantamab or cetuximab, (b) any component of mFOLFOX6 and, (c) any component of FOLFIRI * Has a prior or concurrent second malignancy other than the disease under study or one whose natural history or treatment is likely to interfere with any study endpoints of safety or the efficacy of the study treatment(s) * Participant with known mismatch repair deficiency (dMMR)/ high microsatellite instability (MSI-H) status and human epidermal growth factor receptor 2 (HER2)-positive/amplified tumor * Has prior exposure to any agents that target epidermal growth factor receptor (EGFR), mesenchymal epithelial transition (MET) or vascular endothelial growth factor (VEGF)
What this study is about
In the sponsor’s own words, from the registry.
The purpose of this study is to compare how long the participants are disease-free (progression-free survival) when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, oxaliplatin (mFOLFOX6) or 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride (FOLFIRI) versus cetuximab and mFOLFOX6 or FOLFIRI in adult participants with Kirsten rat sarcoma viral oncogene homolog (KRAS)/ Neuroblastoma RAS viral oncogene homolog (NRAS) and v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) wild type (WT) unresectable or metastatic left-sided colorectal cancer.
What participants receive
- Experimental
Arm A: Amivantamab in Combination With Chemotherapy
Participants will receive amivantamab in combination with chemotherapy (mFOLFOX6 \[chemotherapy consisting of 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and oxaliplatin\] or FOLFIRI \[chemotherapy consisting of 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride\]) for 28-days treatment cycles and will continue to receive the treatment until radiographic disease progression or other discontinuation criteria are met.
Biological: Amivantamab · Drug: 5-fluorouracil · Drug: Leucovorin calcium/Levoleucovorin · Drug: Oxaliplatin · Drug: Irinotecan Hydrochloride
- Active comparator
Arm B: Cetuximab in Combination With Chemotherapy
Participants will receive cetuximab in combination with chemotherapy (mFOLFOX6 or FOLFIRI) for 28-days treatment cycles and will continue to receive the treatment until radiographic disease progression or other discontinuation criteria are met.
Biological: Cetuximab · Drug: 5-fluorouracil · Drug: Leucovorin calcium/Levoleucovorin · Drug: Oxaliplatin · Drug: Irinotecan Hydrochloride
Interventions
AmivantamabBiological
Also known as JNJ-61186372
Amivantamab will be administered.
CetuximabBiological
Also known as Erbitux
Cetuximab will be administered.
5-fluorouracilDrug
5-fluorouracil will be administered as chemotherapy regimen.
Leucovorin calcium/LevoleucovorinDrug
Leucovorin calcium/Levoleucovorin will be administered as chemotherapy regimen.
OxaliplatinDrug
Oxaliplatin will be administered as chemotherapy regimen.
Irinotecan HydrochlorideDrug
Irinotecan hydrochloride will be administered as chemotherapy regimen.
What the study measures
Primary outcomes
Progression-Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR)
PFS is defined as the time from randomization until the date of objective disease progression or death (due to any cause), whichever comes first, as assessed by BICR using response evaluation criteria in solid tumors (RECIST) version (v) 1.1. Participants who have not progressed or have not died at the time of analysis will be censored at their last evaluable RECIST v1.1 assessment date.
Time frame: Up to 4 years and 2 months
Secondary outcomes
Overall Survival (OS)
OS is defined as the time from the date of randomization to the date of participant's death due to any cause. Any participant not known to have died at the time of analysis will be censored based on the last recorded date on which the participant was known to be alive.
Time frame: Up to 7 Years 3 Months
Objective Response Rate (ORR) as Assessed by BICR
ORR is defined as the proportion of randomized participants achieving a best overall response (BOR) of partial response (PR) or complete response (CR), as determined by BICR using RECIST v1.1 criteria. BOR is defined as best response recorded between the date of randomization and the date of first objectively documented progression per RECIST v1.1 or the date of subsequent systemic anti cancer therapy or date of curative-intent procedure, whichever occurs first.
Time frame: Up to 7 Years 3 Months
Objective Response Rate (ORR) as Assessed by Investigator
ORR is defined as the percentage of randomized participants achieving complete CR or PR, as assessed by the investigator.
Time frame: Up to 7 Years 3 Months
Progression Free Survival (PFS) as Assessed by Investigator
PFS is defined as the time from randomization until the date of objective disease progression or death (due to any cause), whichever comes first, as assessed by the investigator. Participants who have not progressed or have not died at the time of analysis will be censored at their last evaluable disease assessment date.
Time frame: Up to 7 Years 3 Months
Duration of Response (DOR) as Assessed by BICR
DOR is defined as time from the date of first documented response (CR or PR) until the date of documented progression or death, whichever comes first, for participants who have PR or CR, as assessed by BICR using RECIST v1.1 criteria.
Time frame: Up to 7 Years 3 Months
Duration of Response (DOR) as Assessed Investigator
DOR is defined as time from the date of first documented response (CR or PR) until the date of documented progression or death, whichever comes first, for participants who have PR or CR, as assessed by the investigator.
Time frame: Up to 7 Years 3 Months
Time to Response (TTR) as Assessed by BICR
TTR is defined as the time from the date of randomization to the date of first documentation of a response (PR or CR) prior to any disease progression or subsequent systemic anti-cancer therapy or curative-intent procedure, for participants who have PR or CR as BOR, as assessed by BICR.
Time frame: Up to 7 Years 3 Months
Time to Response as Assessed by Investigator
TTR is defined as the time from the date of randomization to the date of first documentation of a response (PR or CR) prior to any disease progression or subsequent systemic anti-cancer therapy or curative-intent procedure, for participants who have PR or CR as BOR, as assessed by investigator.
Time frame: Up to 7 Years 3 Months
Progression-free Survival After Subsequent Therapy (PFS2)
PFS2 is defined as the time from randomization until the date of second objective disease progression, after initiation of subsequent anticancer therapy, based on investigator assessment (after that used for PFS) or death, whichever comes first.
Time frame: Up to 7 Years 3 Months
Disease Control Rate (DCR) as Assessed by BICR
DCR is defined as the percentage of randomized participants achieving CR, PR, or stable disease (with minimum duration of 7 weeks) as assessed by BICR using RECIST v1.1 criteria.
Time frame: Up to 7 Years 3 Months
Disease Control Rate (DCR) as Assessed by Investigator
DCR is defined as the percentage of randomized participants achieving CR, PR, or stable disease (with minimum duration of 7 weeks) as assessed by the investigator.
Time frame: Up to 7 Years 3 Months
Time to Treatment Failure
Time to treatment failure is defined as time from randomization to discontinuation of therapy for any reason including death, progression, toxicity, or initiation of new anticancer therapy.
Time frame: Up to 7 Years 3 Months
Curative Resection (R0) Rate
Curative resection (R0) rate is defined as the proportion of participants from the analysis set who underwent curative-intent surgery, where the residual tumor classification was R0.
Time frame: Up to 7 Years 3 Months
Number of Participants with Adverse Events (AEs) by Severity
An AE can be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal (investigational or non-investigational) product. AE severity will be graded according to the national cancer institute common terminology criteria for adverse events (NCI-CTCAE) v5.0. by using the standard grades as follows: Grade 1: Mild; asymptomatic or mild symptoms; Grade 2: Moderate; minimal, local or noninvasive intervention indicated; Grade 3: Severe or medically significant but not immediately life threatening; hospitalization or prolongation of hospitalization indicated; Grade 4: Life-threatening consequences; and Grade 5: Death related to AE.
Time frame: Up to 7 Years 3 Months
Number of Participants with Abnormalities in Laboratory Values
Participants with abnormalities in laboratory values (such as serum chemistry, hematology) will be reported.
Time frame: Up to 7 Years 3 Months
Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Score
The EORTC QLQ-C30, is a self-administered, 30-item questionnaire measuring the health-related quality of life (HRQoL) of participants with cancer. EORTC QLQ-C30 includes 5 functional scales, 3 symptom scales, a global health status / quality of life scale, and 6 single items. Responses to items 1-28 are rated on a 4-point Likert response scale ranging from 1 "Not at all" to 4 "Very much." Two global health status items are rated on a 7-point numeric rating scale from 1 "Very Poor" to 7 "Excellent." Higher scores indicate greater functioning, better global health status, and more severe symptoms.
Time frame: From Baseline up to 7 Years 3 Months
Time to Worsening in Symptoms and Functioning as Measured by EORTC QLQ-C30
The EORTC QLQ-C30, is a self-administered, 30-item questionnaire measuring the HRQoL of participants with cancer. EORTC QLQ-C30 includes 5 functional scales, 3 symptom scales, a global health status / quality of life scale, and 6 single items. Responses to items 1-28 are rated on a 4-point Likert response scale ranging from 1 "Not at all" to 4 "Very much." Two global health status items are rated on a 7-point numeric rating scale from 1 "Very Poor" to 7 "Excellent." Higher scores indicate greater functioning, better global health status, and more severe symptom.
Time frame: Up to 7 Years 3 Months
Change from Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Colorectal Cancer Module 29 (EORTC-QLQ-C29) Score
The EORTC QLQ-CR29, is a self-administered, 29-item questionnaire measuring the HRQoL of participants with colorectal cancer. The QLQ CR29 includes items that evaluate symptoms (gastrointestinal, urinary, pain, and others) and functional areas (sexual, body image, weight, and anxiety) that are associated with colorectal cancer and its treatments. Responses are rated on a 4-point Likert response scale ranging from 1 "Not at all" to 4 "Very much". All scores are linearly converted into a scale from 0 to 100. Higher scores indicate greater functioning and more severe symptoms.
Time frame: From Baseline up to 7 Years 3 Months
Time to Worsening in Symptoms and Functioning as Measured by EORTC QLQ-CR29
The EORTC QLQ-CR29, is a self-administered, 29-item questionnaire measuring the HRQoL of participants with colorectal cancer. The QLQ CR29 includes items that evaluate symptoms (gastrointestinal, urinary, pain, and others) and functional areas (sexual, body image, weight, and anxiety) that are associated with colorectal cancer and its treatments. Responses are rated on a 4-point Likert response scale ranging from 1 "Not at all" to 4 "Very much". All scores are linearly converted into a scale from 0 to 100. Higher scores indicate greater functioning and more severe symptoms.
Time frame: Up to 7 Years 3 Months
Overall Side Effect Burden as Measured by European Organisation for Research and Treatment of Cancer (EORTC) Item 168 Scale Score
The EORTC item 168 is a single item used to measure the overall impact of treatment side effects. Responses are rated on a 4-point Likert response scale ranging from 1 "not at all" to 4 "very much." Higher scores indicate severe side effects.
Time frame: Up to 7 Years 3 Months
Who is running it
- Lead sponsor
- Janssen Research & Development, LLC
- Sponsor type
- Industry
- Responsible party
- The sponsor
- Organisation
- Janssen Research & Development, LLC
- Data monitoring committee
- Yes
- US FDA-regulated drug
- Yes
- US FDA-regulated device
- No
- Sponsor's study ID
- 61186372COR3001
- Other IDs
- 2024-513852-13-00
Janssen Research & Development, LLC Clinical Trial
Study director
Janssen Research & Development, LLC
Study sites(239)
Rajiv Gandhi Cancer Institute and Research Centre
Delhi, India
Recruiting
B P Poddar Hospital and Medical research Limited
Kolkata, India
Recruiting
Tata Memorial Hospital
Mumbai, India
Recruiting
Deenanath Mangeshkar Hospital and Research Centre
Pune, India
Recruiting
Mahamana Pandit Madan Mohan Malviya Cancer Centre
Varanasi, India
Recruiting
Banner MD Anderson Cancer Center
Gilbert, Arizona, United States
Recruiting
St. Bernard's Medical Center
Jonesboro, Arkansas, United States
Recruiting
Highlands Oncology Group
Springdale, Arkansas, United States
Recruiting
CBCC Global Research
Bakersfield, California, United States
Recruiting
Los Angeles Cancer Network
Glendale, California, United States
Recruiting
Cancer and Blood Specialty Clinic
Los Alamitos, California, United States
Recruiting
USC Norris Comprehensive Cancer Center
Los Angeles, California, United States
Recruiting
UCLA
Santa Monica, California, United States
Recruiting
Providence Medical Foundation
Santa Rosa, California, United States
Recruiting
Torrance Memorial Physicians Network
Torrance, California, United States
Recruiting
Rocky Mountain Cancer Centers
Denver, Colorado, United States
Recruiting
Yale University School Of Medicine
New Haven, Connecticut, United States
Recruiting
Georgetown Univ Medical Center Lombardi Cancer Center
Washington D.C., District of Columbia, United States
Recruiting
Florida Cancer Specialists South
Fort Myers, Florida, United States
Recruiting
AdventHealth Medical Group Oncology and Hematology at Orlando
Orlando, Florida, United States
Recruiting
Florida Cancer Specialists North Region
St. Petersburg, Florida, United States
Recruiting
Florida Cancer Specialists East
West Palm Beach, Florida, United States
Recruiting
Grady Memorial Hospital
Atlanta, Georgia, United States
Recruiting
Winship Cancer Institute Emory University
Atlanta, Georgia, United States
Recruiting
Illinois Cancer Specialists
Arlington Heights, Illinois, United States
Recruiting
Illinois CancerCare
Peoria, Illinois, United States
Recruiting
Fort Wayne Medical Oncology & Hematology
Fort Wayne, Indiana, United States
Recruiting
University of Iowa Hospital
Iowa City, Iowa, United States
Recruiting
Mission Cancer Blood
Waukee, Iowa, United States
Recruiting
Cancer Center of Kansas
Wichita, Kansas, United States
Recruiting
Ochsner Clinic Foundation
New Orleans, Louisiana, United States
Recruiting
MedStar Franklin Square Medical Center
Baltimore, Maryland, United States
Recruiting
Frederick Health Hospital - James M Stockman Cancer Institute
Frederick, Maryland, United States
Recruiting
VA Ann Arbor Healthcare System
Ann Arbor, Michigan, United States
Recruiting
University of Michigan
Ann Arbor, Michigan, United States
Recruiting
Henry Ford Hospital
Detroit, Michigan, United States
Recruiting
Cancer And Hematology Centers of Western Michigan PC
Grand Rapids, Michigan, United States
Recruiting
Hattiesburg Clinic
Hattiesburg, Mississippi, United States
Recruiting
Washington University School Of Medicine
St Louis, Missouri, United States
Recruiting
Nebraska Cancer Specialists Midwest Cancer Center
Omaha, Nebraska, United States
Recruiting
Showing 40 of 239 sites. 233 recruiting, 6 not recruiting and 0 cancelled; 5 in India. Not recruiting covers sites not yet open, finished enrolling, completed or paused; cancelled covers sites withdrawn before opening or stopped for good.
References and data sharing
- Participant data shared
- Yes
The data sharing policy of Johnson \& Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Source: ClinicalTrials.gov record NCT06662786, status verified November 2026. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Interested in this study?
Tell us how to reach you and we will connect you with the study team. Or refer someone you care for, with their permission.